Connect with us

Survector (amineptine)


Amineptine (or SURVECTOR®) was mainly prescribed to treat major depressive disorder.

Status: DISCONTINUED

Class: Atypical, Tricyclic (TCA)

FDA Approval: International Only (Europe)

Dosage Forms: N/A

Biological Half-life: 0.8-1 hour

Side Effects: Dizziness, blurred vision, dry mouth, nausea, constipation, appetite changes, hyperhidrosis, sex drive changes

Routes of Administration: Oral

Pregnancy Category: N/A

  www.fda.gov

Advertisement

Twitter Feed

Gene discovery may explain why Lithium doesn't work for all patients https://t.co/yuLLmG8hAa

Researchers found insomnia may increase risk of mood disorder in teens https://t.co/tKiFr3uvMF #mentalhealth @PittTweet

Can Tylenol provide relief for social media anxiety? https://t.co/fC7sKZrXw4 #FOMO #socialanxiety #cyberpsychology

Advertisement